10-K: Lifeward (Formerly ReWalk Robotics) Reports Record 2023 Revenue Following AlterG Acquisition and Medicare Policy Change

Lifeward, formerly ReWalk Robotics, announced record annual revenue of $13.9 million for 2023, driven by the acquisition of AlterG and positive developments in Medicare coverage for exoskeletons.

Summary

• Lifeward, previously known as ReWalk Robotics, reported a significant increase in revenue for 2023, reaching $13.9 million compared to $5.5 million in 2022.
• This 151% growth was primarily fueled by the acquisition of AlterG in August 2023, which contributed $7.7 million to the total revenue.
• The company also saw increased revenue from ReWalk Personal Exoskeletons and MyoCycle products.
• A key development was the Centers for Medicare & Medicaid Services (CMS) policy change, effective January 1, 2024, which includes personal exoskeletons in the Medicare brace benefit category.
• CMS has proposed a preliminary payment determination of $94,617 for the ReWalk Personal Exoskeleton, with a final determination expected in the first quarter of 2024 and an effective date of April 1, 2024.
• The company's cash position remains strong at $28.1 million as of December 31, 2023, with no debt.
• Lifeward is also focused on expanding commercial and other reimbursement coverage and penetrating facilities that could utilize AlterG systems.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative factors. The record revenue and CMS policy change are very positive, but the ongoing losses and need for additional capital raise concerns. The sentiment is cautiously optimistic.

Positives

• The acquisition of AlterG significantly expanded the company's revenue base and product portfolio.
• The FDA clearance for stair and curb functionality enhances the real-world usability of the ReWalk Personal Exoskeleton.
• The CMS policy change provides a clear path for Medicare reimbursement of personal exoskeletons.
• The company has a strong cash position with no debt.
• The company is actively working to expand reimbursement coverage and market penetration.

Negatives

• The company incurred a net loss of $22.1 million for 2023.
• The company has a history of losses and is dependent on raising additional capital.
• The company is subject to limitations on its ability to use Form S-3 for equity raises.
• The company relies on a single third-party supplier for some of its products.
• The company faces competition from other medical exoskeleton and rehabilitation device companies.

Risks

• The company may fail to realize the anticipated benefits from the AlterG acquisition.
• Global economic weakness and uncertainty could negatively impact demand for the company's products.
• The company may not have sufficient funds to meet future operating needs or capital requirements.
• The company faces economic and political risks associated with doing business in Taiwan and Russia.
• The company may not be able to maintain compliance with Nasdaq listing requirements.
• The company's future growth depends on its ability to develop and commercialize new products.
• The market for medical exoskeletons remains relatively new and unproven.
• The company may fail to secure or maintain adequate insurance coverage or reimbursement for its products.
• Defects in the company's products or software could adversely affect its operations.
• The company may be subject to product liability claims.
• The company may not be able to leverage its sales, marketing, and training infrastructure.
• The potential health benefits of the company's products have not been substantiated by long-term clinical data.
• The company depends on a single third-party supplier to manufacture some of its products.
• The company operates in a competitive industry that is subject to rapid technological change.
• The company may fail to enhance its exoskeleton product offerings through research and development.
• The company may enter into collaborations that do not result in commercially viable products.
• The company may seek to grow its business through acquisitions that it fails to manage or integrate.
• The company's products are subject to extensive governmental regulations.
• The company may fail to comply with U.S. anti-kickback, false claims, and other healthcare fraud and abuse laws.
• The company's products may not receive adequate coverage and reimbursement from third-party payors.
• The company's business may be affected by U.S. healthcare reform measures.
• The company's business may be affected by cybersecurity attacks or incidents.
• The company's success depends on its ability to obtain and maintain protection for its intellectual property.
• The company may be subject to patent infringement claims.
• Sales of a substantial number of ordinary shares by the company or its large shareholders could adversely affect the value of its ordinary shares.
• The company may be characterized as a passive foreign investment company, which could have adverse tax consequences for U.S. holders of its ordinary shares.
• The price of the company's ordinary shares may be volatile.
• Conditions in Israel may materially and adversely affect the company's business and results of operations.
• The company's operations may be disrupted as a result of the obligation of Israeli citizens to perform military service.
• The company's sales may be adversely affected by boycotts of Israel.
• The tax benefits that are available to the company may be terminated or reduced in the future.
• The company may be subject to claims for remuneration or royalties for assigned service invention rights by its employees.
• Provisions of Israeli law and the company's Articles of Association may delay, prevent, or otherwise impede a merger with, or an acquisition of, the company.
• It may be difficult to enforce a judgment of a U.S. court against the company, its officers, and directors, to assert U.S. securities laws claims in Israel or to serve process on the company's officers and directors.
• The company's business could be negatively affected as a result of actions of activist shareholders.
• Exchange rate fluctuations between the U.S. dollar, the euro and the NIS may negatively affect the company's earnings.
• The company is subject to certain regulatory regimes that may affect the way that it conducts business internationally.
• The company's business may be materially affected by changes to fiscal and tax policies.
• The company may be characterized as a controlled foreign corporation, which could have adverse tax consequences for U.S. holders of its ordinary shares.
• Significant disruptions in the company's information technology systems could adversely affect its business.
• If the company fails to properly manage its anticipated growth, its business could suffer.
• The company is highly dependent on the knowledge and skills of its senior management.
• Shutdowns of the U.S. federal government could materially impair the company's business and financial condition.

Future Outlook

The company intends to aggressively target the eligible Medicare customer base for growth while also continuing to focus on expanding commercial and other reimbursement coverage. Additionally, with increased direct sales resources and distributor network, the company also expects to greater penetrate the base of facilities which could utilize AlterG systems for rehabilitation of their patients.

Management Comments

• The company has created a U.S. commercial team that it believes has the capacity and capabilities to support a broad range of physical and neurological rehabilitation products for use in facilities, the home and the community.
• The company has rebranded under the name Lifeward, to emphasize its commitment to pioneering a portfolio of innovative technologies to empower the pursuit of lifes ambitions in the face of physical limitation or disability.

Industry Context

The announcement reflects a growing trend in the medical device industry towards innovative rehabilitation technologies and the increasing recognition of the benefits of exoskeletons for individuals with mobility impairments. The CMS policy change is a significant step towards broader adoption of these technologies.

Comparison to Industry Standards

• The company's revenue growth of 151% is significantly higher than the average growth rate for the medical device industry, which is typically in the single-digit to low double-digit range.
• The company's gross margin of 32% is lower than the average gross margin for medical device companies, which is typically in the 50-70% range. This is likely due to the company's reliance on third-party manufacturing and the high cost of its products.
• The company's operating loss of $23.6 million is a concern, as many medical device companies aim to achieve profitability within a few years of commercialization. However, the company's recent acquisition and the CMS policy change may improve its profitability in the future.
• The company's cash position of $28.1 million is relatively strong for a company of its size, but it will need to continue to raise capital to fund its operations and growth.

Stakeholder Impact

• Shareholders may benefit from the increased revenue and potential for future growth, but also face the risk of dilution from future capital raises.
• Employees may benefit from the company's growth and expansion, but also face the risk of job losses due to restructuring.
• Customers may benefit from the company's innovative products and services, but also face the risk of product defects or recalls.
• Suppliers may benefit from the company's increased demand for its products, but also face the risk of supply chain disruptions.
• Creditors may benefit from the company's strong cash position, but also face the risk of default if the company's financial performance deteriorates.

Next Steps

• The company intends to aggressively target the eligible Medicare customer base for growth.
• The company will continue to focus on expanding commercial and other reimbursement coverage.
• The company will work to penetrate the base of facilities which could utilize AlterG systems for rehabilitation of their patients.
• The company will continue to develop new products and technologies.

Key Dates

Keywords

exoskeleton, rehabilitation, medical devices, AlterG, ReWalk, ReStore, Medicare, CMS, spinal cord injury, stroke, FDA, reimbursement, healthcare, robotic, mobility